Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

40.41 -0.09 (-0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,066
Open 39.92
Bid (Size) 39.00 (100)
Ask (Size) 41.00 (200)
Prev. Close 40.50
Today's Range 39.47 - 40.63
52wk Range 3.810 - 57.14
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NANOBIOTIX Announces Closing of Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
From Nanobiotix S.A.
Via GlobeNewswire

Performance

YTD
+82.6%
+82.6%
1 Month
+22.0%
+22.0%
3 Month
+56.6%
+56.6%
6 Month
+98.3%
+98.3%
1 Year
+960.6%
+960.6%

More News

Read More
News headline image
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Launch of Global Follow-On Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Statement Regarding Recent Media Speculation
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Investor Conferences in March
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue ↗
Via The Motley Fool
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire

Frequently Asked Questions

Is Nanobiotix S.A. - ADSs publicly traded?
Yes, Nanobiotix S.A. - ADSs is publicly traded.
What exchange does Nanobiotix S.A. - ADSs trade on?
Nanobiotix S.A. - ADSs trades on the Nasdaq Stock Market
What is the ticker symbol for Nanobiotix S.A. - ADSs?
The ticker symbol for Nanobiotix S.A. - ADSs is NBTX on the Nasdaq Stock Market
What is the current price of Nanobiotix S.A. - ADSs?
The current price of Nanobiotix S.A. - ADSs is 40.41
When was Nanobiotix S.A. - ADSs last traded?
The last trade of Nanobiotix S.A. - ADSs was at 05/28/26 04:00 PM ET
What is the market capitalization of Nanobiotix S.A. - ADSs?
The market capitalization of Nanobiotix S.A. - ADSs is 1.39B
How many shares of Nanobiotix S.A. - ADSs are outstanding?
Nanobiotix S.A. - ADSs has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.